Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

AstraZeneca : says its Oxford vaccine deal allows it to add up to 20% of manufacturing costs

10/23/2020 | 11:55pm EST
A sign marks an AstraZeneca facility in Waltham

stra(Reuters) - AstraZeneca Plc said on Friday its coronavirus vaccine deal with Oxford University will allow it to add up to 20% of manufacturing costs to cover additional expenses required to be incurred by the British drugmaker.

"In addition to the manufacturing costs, the company is incurring costs in excess of $1 billion globally that include clinical development, regulatory, distribution, pharmacovigilance and other expenses", an AstraZeneca spokesman said in a statement.

"To cover these additional expenses, the company will add an amount equivalent to a maximum of 20% of the manufacturing costs to ensure there is no material impact on its finances this year while continuing efforts to provide the vaccine at no profit during the pandemic," the statement added.

AstraZeneca has previously signed multiple supply-and-manufacture deals for more than 3 billion doses globally.

These agreements are with companies and governments as the company gets closer to reporting early results of a late-stage clinical trial. Developed by the University of Oxford and licensed to AstraZeneca in April, the vaccine is expected to be one of the first from big pharma to secure regulatory approval.

The company had said earlier it has created multiple supply chains to ensure that access to its vaccine is timely, broad and equitable for high- and low-income countries alike.

Pricing and supply of experimental COVID-19 vaccines have been widely debated as richer countries pump billions of dollars into funding, and AstraZeneca has also been granted protection from future liability claims.

Separately, AstraZeneca resumed the U.S. trial of its experimental COVID-19 vaccine after approval by regulators, the company said on Friday.

(Reporting by Kanishka Singh; editing by Grant McCool)

By Kanishka Singh

© Reuters 2020
All news about ASTRAZENECA PLC
05:27pGlobal equity markets jump, bonds dip, on hopes of vaccine-led recovery
05:20pBrazil sees one-dose, unfrozen vaccine as ideal for COVID-19 -official
04:23pGlobal equity markets jump, bonds dip, on hopes of vaccine-led recovery
08:58aIONIS PHARMACEUTICALS : announces AstraZeneca's initiation of the Phase 2b clini..
08:52aCOVID-19 vaccine sprint as Pfizer-BioNTech, Moderna seek emergency EU approva..
06:12aASTRAZENECA : Crestor to be divested to Grünenthal in Europe
04:03aASTRAZENECA : sells former blockbuster cholesterol drug for $320 million
03:55aASTRAZENECA : Phakamisa Programme marks 10 years since launch with programme exp..
02:30aASTRAZENECA : to Sell Crestor Rights in Europe for Up to $350 Million
02:05aASTRAZENECA : Phakamisa Programme marks 10 years since launch with programme exp..
More news
Financials (USD)
Sales 2020 26 494 M - -
Net income 2020 2 998 M - -
Net Debt 2020 13 181 M - -
P/E ratio 2020 44,0x
Yield 2020 2,69%
Capitalization 137 B 137 B -
EV / Sales 2020 5,68x
EV / Sales 2021 4,95x
Nbr of Employees 70 600
Free-Float 95,7%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 121,91 $
Last Close Price 104,68 $
Spread / Highest target 48,5%
Spread / Average Target 16,5%
Spread / Lowest Target -36,9%
EPS Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-0.82%380 876
ROCHE HOLDING AG-4.76%282 467
PFIZER, INC.3.21%212 942
NOVARTIS AG-10.48%206 479
MERCK & CO., INC.-11.61%203 389